Whether “[t]he panel overlooked appellant’s argument that there was ‘a longfelt need for an effective AA treatment with a tolerable long-term side effect profile’ . . . . That is, [whether] the panel failed to recognize that appellant’s argument was not limited to a long-felt need for an already-FDA-approved AA treatment.”
